Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2002-12-04
2008-09-30
Saunders, David A (Department: 1644)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C435S007240
Reexamination Certificate
active
07429374
ABSTRACT:
The subject invention provides a process for measuring the relative potency of a test batch of glatiramer acetate. In addition, the subject invention provides a process for preparing a batch of glatiramer acetate as acceptable for pharmaceutical use.
REFERENCES:
patent: 3849550 (1974-11-01), Teitelbaum et al.
patent: 3991210 (1976-11-01), Shea
patent: 4129666 (1978-12-01), Wizerkaniuk
patent: 4339431 (1982-07-01), Gaffar
patent: 4594409 (1986-06-01), Hayashi et al.
patent: 5204099 (1993-04-01), Barbier et al.
patent: 5554372 (1996-09-01), Hunter et al.
patent: 5583031 (1996-12-01), Stern
patent: 5591629 (1997-01-01), Rodriguez et al.
patent: 5623052 (1997-04-01), McLean et al.
patent: 5627206 (1997-05-01), Hupe et al.
patent: 5668117 (1997-09-01), Shapiro
patent: 5716946 (1998-02-01), DeLuca et al.
patent: 5719269 (1998-02-01), Schwarz et al.
patent: 5719296 (1998-02-01), Acton, III et al.
patent: 5734023 (1998-03-01), Nag et al.
patent: 5800808 (1998-09-01), Konfino et al.
patent: 5858964 (1999-01-01), Aharoni et al.
patent: 5886156 (1999-03-01), McLean et al.
patent: 5958972 (1999-09-01), Hupe et al.
patent: 5965600 (1999-10-01), Sato et al.
patent: 5981589 (1999-11-01), Konfino et al.
patent: 6024981 (2000-02-01), Khankari et al.
patent: 6048898 (2000-04-01), Konfino et al.
patent: 6054430 (2000-04-01), Konfino et al.
patent: 6162800 (2000-12-01), Dolle et al.
patent: 6214791 (2001-04-01), Arnon et al.
patent: 6342476 (2002-01-01), Konfino et al.
patent: 6362161 (2002-03-01), Konfino et al.
patent: 6369099 (2002-04-01), DeLuca et al.
patent: 6514938 (2003-02-01), Gad et al.
patent: 6620847 (2003-09-01), Konfino et al.
patent: 6800285 (2004-10-01), Rodriguez et al.
patent: 6800287 (2004-10-01), Gad et al.
patent: 6844314 (2005-01-01), Eisenbach-Schwartz et al.
patent: 6939539 (2005-09-01), Konfino et al.
patent: 7022663 (2006-04-01), Gilbert et al.
patent: 7033582 (2006-04-01), Yong et al.
patent: 7074580 (2006-07-01), Gad et al.
patent: 7163802 (2007-01-01), Gad et al.
patent: 7199098 (2007-04-01), Konfino et al.
patent: 7279172 (2007-10-01), Aharoni et al.
patent: 2001/0055568 (2001-12-01), Gilbert et al.
patent: 2002/0037848 (2002-03-01), Eisenbach-Schwartz et al.
patent: 2002/0055466 (2002-05-01), Aharoni et al.
patent: 2002/0077278 (2002-06-01), Yong et al.
patent: 2002/0107388 (2002-08-01), Vanderback
patent: 2002/0115103 (2002-08-01), Gad et al.
patent: 2002/0182210 (2002-12-01), Rodriguez et al.
patent: 2003/0004099 (2003-01-01), Eisenbach-Schwartz et al.
patent: 2003/0170729 (2003-09-01), Klinger
patent: 2004/0006022 (2004-01-01), Strominger et al.
patent: 2004/0106554 (2004-06-01), Konfino et al.
patent: 2004/0178388 (2004-09-01), Mumper et al.
patent: 2005/0014694 (2005-01-01), Yong et al.
patent: 2005/0019322 (2005-01-01), Rodriguez et al.
patent: 2005/0038233 (2005-02-01), Gad et al.
patent: 2005/0170004 (2005-08-01), Rosenberger et al.
patent: 2005/0171286 (2005-08-01), Konfino et al.
patent: 2005/0256046 (2005-11-01), Gad et al.
patent: 2006/0052586 (2006-03-01), Dolitzky
patent: 2006/0122113 (2006-06-01), Pinchasi et al.
patent: 2006/0172942 (2006-08-01), Dolitzky
patent: 2007/0021341 (2007-01-01), Sela et al.
patent: 2007/0048794 (2007-03-01), Gad et al.
patent: 2007/0054857 (2007-03-01), Pinchasi et al.
patent: 3930733 (1991-03-01), None
patent: 0378246 (1986-06-01), None
patent: 0383620 (1990-08-01), None
patent: 0359783 (1995-11-01), None
patent: 1292279 (2003-03-01), None
patent: 254496 (1990-08-01), None
patent: 336690 (1998-01-01), None
patent: 980214 (1999-09-01), None
patent: 1182051 (1985-09-01), None
patent: 1664845 (1991-07-01), None
patent: 1690368 (1995-08-01), None
patent: 1469826 (1995-11-01), None
patent: WO 8810120 (1988-12-01), None
patent: WO 9202543 (1992-02-01), None
patent: WO 9403484 (1994-02-01), None
patent: WO 9426774 (1994-11-01), None
patent: WO 9526980 (1995-10-01), None
patent: WO 9531990 (1995-11-01), None
patent: WO 9531997 (1995-11-01), None
patent: WO 9533475 (1995-12-01), None
patent: WO 9830227 (1998-07-01), None
patent: WO 0005249 (2000-02-01), None
patent: WO 0005250 (2000-02-01), None
patent: WO 0018794 (2000-04-01), None
patent: WO 0020010 (2000-04-01), None
patent: WO 0027417 (2000-05-01), None
patent: WO 0152878 (2001-07-01), None
patent: 0160392 (2001-08-01), None
patent: WO 0185797 (2001-11-01), None
patent: WO 0193828 (2001-12-01), None
patent: WO 0193893 (2001-12-01), None
patent: WO 0197846 (2001-12-01), None
patent: WO02076503 (2002-10-01), None
patent: 03048735 (2003-06-01), None
patent: 05041933 (2003-06-01), None
patent: 2004043995 (2004-05-01), None
patent: 06050122 (2006-05-01), None
patent: 08006026 (2008-01-01), None
Aharoni, R. et al., (1998) “Bystander Suppression of Experimental Autoimmune Encephalomyelitis by T cell Lines and Clones of the Th2 Type Induced by Copolymer 1”, Journal of Neuroimmunology, vol. 91, No. 1-2, pp. 135-146.
Aharoni, R. et al., (1993) “T Suppressor Hybridomas and Interleukin-2-Dependent Lines Induced by Copolymer 1 or by Spinal Cord Homogenate Down-Regulate Experimental Allergic Encephalomyelitis”, Eur. J. Immunol., vol. 23, pp. 17-25.
Wiesemann, et al., (2001) “Glatiramer Acetate Induces IL-13/Il-5 Secretion in Native T Cells”, Journal of Neuroimmunology, vol. 119, No. 1, pp. 137-144.
Teitelbaum, (1992) “Synthetic Copolymer 1 Inhibits Human T-cell Lines Specific for Myelin Basic Protein”, Proc. Natl. Acad. Sci. USA, vol. 89, pp. 137-141.
Aharoni (1997) “Copolymer 1 Induces T Cells of the T Helper Type 2 that Crossreact with Myelin Basic Protein and Suppress Experimental Autoimmune Encephalomyelitis”, Proc. Natl. Acad. Sci. USA, vol. 94, pp. 10821-10826.
Johnson, K.P., (1995) Neurology, vol. 45, pp. 1268-1276 (Abstract only).
Lando et al., (1979) “Effect of Cyclophosphamide on Suppressor Cell Activity in Mice Unresponsive to EAE”, J. Immunol., vol. 123, No. 5, pp. 2156-2160.
“Copaxone” inPhysician's Desk Reference, 2000, Medical Economics Co., Inc., Montvale, NJ, 3115.
Arnon, et al., “Suppression of Demyelinating Diseases by Synthetic Copolymers”,A Multidisciplinary Approach to Myelin Disease(G. Serlupi Crescenzi, ed., Plenum Publishing Corp., 1988) 243-250.
Arnon, et al., “Suppression of Experimental Allergic Encephalomyelitis by Cop-1-Relevance to Multiple Sclerosis”,Israel J. Med. Sci., 1989, 25, 686-689.
Arnon, et al., “On the Existence of Suppressor Cells”,Int. Arch. Allergy Immunol., 1993, 100, 27.
Arnon, et al., “Immunomodulation of Experimental Allergic Encephalomyelitis”,Israel J. Med. Sci., 1993, 29, 175-181.
Arnon, et al., “Immunospecific Drug Design—Prospects for Treatment of Autoimmune Disease”,Therapeutic Immunol., 1994, 1, 65-70.
Asakura and Rodriguez, “A Unique Population of Circulating Autoantibodies Promotes Central Nervous System Remyelination”,Multiple Sclerosis, 1998 4: 217-221.
Asakura et al., “Targeting of IgMκ Antibodies to Oligodendrocytes Promotes CNS Remyelination”,J. Neurosci., 1998, 18(19): 7700-7708.
Babu et al., “Reevaluation of Response Patterns of Nonresponder Mice to GIPhe Polymers”,Immunogen., 1983, 18(1): 97-100 (Abstract).
Babu et al., “Ir Gene Control of T and B Cell Responses to Determinants in (Glu Lys Ala) Terpolymer”,J. Immunogenet., 1984, 11(3-4): 251-254 (Abstract).
Bansil, et al., “Multiple Sclerosis: Pathogenesis and Treatment”,Seminars in Neurol., Jun. 1994, 14(2), 146-153.
Baumhefner, et al., “Copolymer 1 as Therapy for Multiple Sclerosis: The Cons”,Neurol., 1988, 38(Suppl. 2), 69-71.
Baxevanis et al., “Genetic Control of T-Cell Proliferative Responses to Poly (Glu40Ala60) and Poly (Glu51Lys34Tyr15): Subregion-Specific Inhibition of the Responses with Monoclonal la Antibodies”,Immunogenetics, 1980, 11: 617-628.
Ben-Nun, et al., “The Autoimmune Reactivity to Myelin Oligodendrocyte Glycoprotein (MOG) in Multiple Sclerosis is Potentially Pathogenic: Ef
Cooper & Dunham LLP
Saunders David A
Teva Pharmaceutical Industries Ltd.
White John P.
LandOfFree
Process for the measurement of the potency of glatiramer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the measurement of the potency of glatiramer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the measurement of the potency of glatiramer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3989760